Company intelligence / Profile preview

Phytomedics

Jamesburg, New Jersey, United Statesphyto-medics.com ↗

Ownership: Private
Development stage: Other

Overview

Phytomedics has advanced a lead botanical drug candidate, PMI‑001, for rheumatoid arthritis into Phase III development following successful Phase II results. The company also develops additional clinical candidates targeting metabolic and age-related diseases. Its proprietary platform enables the discovery and manufacture of novel multi-component pharmaceuticals using plant biotechnology and rhizosecretion technology for cost-effective recombinant protein production.

Therapeutic areas: ImmunologyEndocrinologyOther
Modalities: Small moleculeRecombinant proteinBotanical drug (multi-component botanical therapeutics)
Industry: Biotech

Drug pipeline

3 assets

PMI-001

Unknown

2 more assets in the full pipeline.

Request access →

Beyond the preview

Go deeper on Phytomedics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Phytomedics.

Explore the full profile